Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation.
The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. MCI-154 in doses of 10-100 micrograms improved the cardiac function curve and restored it to the control level at 100 micrograms. At this dose, MCI-154 neither produced an increase in heart rate beyond the control value nor induced arrhythmias. The effects of MCI-154 were not affected by atenolol, a cardioselective beta 1-blocker. These results indicate that MCI-154 would be of potential use in the treatment of heart failure.
Satoh
K
K
Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.
Nunoki
K
K
Goto
T
T
Hosono
M
M
Hashimoto
H
H
Sato
Y
Y
Taira
N
N
D000818:Animals; D001262:Atenolol / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D010424:Pentobarbital / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology* / Q000627:therapeutic use
D002316:Cardiotonic Agents; D011724:Pyridazines; D001262:Atenolol; C052228:MCI 154; D010424:Pentobarbital